Therapeutic Asset Ratings

283 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Tucidinostat Newly Diagnosed	The First Affiliated Hospital of Soochow University	P2	CCC (53)
UREA, N-(2-CHLOROETHYL)-N'-(4-METHYLCYCLOHEXYL)-N-NITROSO- Azacytidine	The First Affiliated Hospital of Soochow University	P2	CCC (53)
UREA, N-(2-CHLOROETHYL)-N'-(4-METHYLCYCLOHEXYL)-N-NITROSO- Conditioning Therapy	The First Affiliated Hospital of Soochow University	P2	CCC (53)
UREA, N-(2-CHLOROETHYL)-N'-(4-METHYLCYCLOHEXYL)-N-NITROSO- MDS	The First Affiliated Hospital of Soochow University	P2	CCC (53)
UREA, N-(2-CHLOROETHYL)-N'-(4-METHYLCYCLOHEXYL)-N-NITROSO- SHR2554	The First Affiliated Hospital of Soochow University	P2	CCC (53)
Vach Newly Diagnosed	The First Affiliated Hospital of Soochow University	P2	CCC (53)
Venetoclax Adult T-Cell Leukemia/Lymphoma	The First Affiliated Hospital of Soochow University	P2	CCC (53)
Venetoclax Consolidation Therapy	The First Affiliated Hospital of Soochow University	P2	CCC (53)
Venetoclax High Risk	The First Affiliated Hospital of Soochow University	P2	CCC (53)
Venetoclax IDH1 Gene Mutation	The First Affiliated Hospital of Soochow University	P2	CCC (53)
Venetoclax Ivosidenib	The First Affiliated Hospital of Soochow University	P2	CCC (53)
Venetoclax Recruiting	The First Affiliated Hospital of Soochow University	P2	CCC (53)
VINCRISTINE SULFATE Effects of Chemotherapy	The First Affiliated Hospital of Soochow University	P2	CCC (53)
VINCRISTINE SULFATE Safety Issues	The First Affiliated Hospital of Soochow University	P2	CCC (53)
VINDESINE Adult T-Cell Leukemia/Lymphoma	The First Affiliated Hospital of Soochow University	P2	CCC (53)
Zanubrutinib Neoplasm	The First Affiliated Hospital of Soochow University	P2	CCC (53)
Zanubrutinib Safety Issues	The First Affiliated Hospital of Soochow University	P2	CCC (53)
UREA, N-(2-CHLOROETHYL)-N'-(4-METHYLCYCLOHEXYL)-N-NITROSO- Acute Myeloid Leukemia	The First Affiliated Hospital of Soochow University	P2/3	CCC (52)
Blinatumomab Immunotherapy	The First Affiliated Hospital of Soochow University	P2	CCC (51)
cd19+cd22 car-t B-Cell Acute Lymphoblastic Leukemia	The First Affiliated Hospital of Soochow University	P2	CCC (51)
Decitabine B-Cell Acute Lymphoblastic Leukemia	The First Affiliated Hospital of Soochow University	P2	CCC (51)
Flumatinib Acute Lymphoblastic Leukemia	The First Affiliated Hospital of Soochow University	P2	CCC (51)
HUMAN PERIPHERAL BLOOD LEUKOCYTES B-Cell Non-Hodgkin Lymphoma	The First Affiliated Hospital of Soochow University	P2	CCC (51)
Inotuzumab Ozogamicin Immunotherapy	The First Affiliated Hospital of Soochow University	P2	CCC (51)
Olverembatinib Acute Leukemia	The First Affiliated Hospital of Soochow University	P2	CCC (51)

Showing 176 to 200 of 283 assets

PreviousPage 8 of 12Next